Shares of Miromatrix (NASDAQ: MIRO) plunged more than 15% in after-hours trading on Wednesday after the life sciences company announced that the U.S. FDA had placed a clinical hold on its investigational New Drug (IND) application for Miroliverelap for the treatment of acute liver failure.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The company submitted the IND application in mid-November.
MIRO stock has plunged more than 34% in the past year.
